ClinicalTrials.gg
RecruitingNCT05642377Updated Mar 21, 2024

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects

A Phase 1 interventional study of HGR4113 and Placebo in Diabetes Mellitus, Type 2, sponsored by Glaceum. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Glaceum · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Planned enrollment
392nd of 493
40 · median 174
Started
2022
with 24 others
Phase 1
95 of 571
8 open now
Primary completion
2024-07
later than 7 of 83 live
Registered
446th of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 392nd largest by planned enrollment of the 493 interventional ones that give a count, is one of 25 that started in 2022, is one of 95 in phase 1, reaches primary completion later than 7 of the 83 other live ones, and was the 446th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

  1. Study Objective: The objective of this study is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics, and food effect of HGR4113 after single and multiple oral administration in healthy subjects.
  2. Study Design and Plan: This study is a randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase 1 clinical trial. Volunteers who have been deemed eligible based on the inclusion/exclusion criteria will be given a random number. Each subject will be assigned to one of the dose groups in a 6:2 ratio to HGR4113 (active) or placebo. Subjects will be studied in a double-blind manner and will receive the investigational product per protocol. Dose will be escalated once safety data is collected up to the last pharmacokinetic blood collection timepoint and safety and tolerability has been deemed acceptable following the review of the Safety Review Committee. Assessments including vital signs, 12-lead ECG, clinical laboratory, reproductive hormones, physical examination, and monitoring of adverse events concomitant medications will be conducted to evaluate safety and tolerability. Blood will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics.
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an form approved by the IRB before Screening.
  2. Adult volunteers between 19 and 50 years of age at Screening.
  3. (BMI) between 18.0 and 24.9.

    ☞ BMI (kg/m\^2) = body weight (kg) / (height [m])\^2

  4. In good health, determined by no findings from medical history, physical examination, vital signs, 12-lead , and clinical laboratory tests at Screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, or cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).
  2. History of stomach or intestinal disorders (e.g., Chron's disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the safety or pharmacokinetic/pharmacodynamic evaluation of the product.
  3. Significant history or clinical manifestation of to any drug including licorice or other drug (e.g., aspirin, antibiotics).
  4. One or more of the following laboratory test results at Screening:

    • ANC \< 1000
    • , ALT, GGT, total > 1.5x upper limit normal
    • Fasting glucose ≥ 126 mg/dL or ≥ 6.5% despite two retests
    • \< 60 (CKD-EPI).
  5. Systolic blood pressure \< 90 mmHg or > 150 mmHg, or diastolic blood pressure \< 60 mgHg or > 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.
  6. History of drug/chemical abuse or tested positive in urine drug screen.
  7. Used or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.
  8. Participation in any clinical study or bioequivalence study within 6 months prior to dosing.
  9. Whole blood donation within 2 months prior to dosing, plasma/ donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.
  10. Alcohol consumption > 21 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol 3 days prior to first dosing until the last pharmacokinetic blood sampling.
  11. History of smoking within 90 days prior to dosing (however, participation is acceptable if the subject has quit at least 90 days prior to dosing) or unable to abstain from smoking 90 days prior to dosing until the last pharmacokinetic blood sampling.
  12. Ingestion of grapefruit-containing foods or beverages 24 hours 3 days prior to dosing until the last pharmacokinetic blood sampling, or unable to abstain from ingesting such foods or beverages during the same period.
  13. Unable to abstain from ingesting caffeine-containing foods or beverages (e.g., coffee, tea [e.g., black tea, green tea], soft drinks, coffee milk, energy drinks, sports drinks) 3 days prior to dosing until the last pharmacokinetic blood sampling.
  14. Females, excluding those who have amenorrhea for at least 12 months or have been surgically sterilized (e.g., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), who are pregnant or lactating, evidenced by a positive urine hCG pregnancy test.
  15. Subject or subject's partner is unable or unwilling to use a medically acceptable means of during and for 90 days following the last dosing or willing to donate sperm during the same period.

    • Acceptable contraceptive methods include:
    • Use of an intrauterine device that has been proven highly effective
    • Male or female physical contraceptive used with chemical sterilization
    • Surgical sterilization of the subject or the subject's partner (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy).
  16. Subjects who, in the opinion of the Investigator, should not participate in in this study based on other reasons.
  17. Subject who is confirmed as the CYP2C19 poor metabolizer (e.g., *2/*2, *2/*3, *3/*3) by exploratory genotyping test at Screening in MAD group.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HGR4113 300 mg Single Dose

    Single oral dosing of HGR4113 300 mg

    Drug: HGR4113

  • Placebo comparator
    Placebo 300 mg Single Dose

    Single oral dosing of placebo 300 mg

    Drug: Placebo

  • Experimental
    HGR4113 600 mg Single Dose

    Single oral dosing of HGR4113600 mg

    Drug: HGR4113

  • Placebo comparator
    Placebo 600 mg Single Dose

    Single oral dosing of placebo 600 mg

    Drug: Placebo

  • Experimental
    HGR4113 1200 mg Single Dose

    Single oral dosing of HGR41131200 mg

    Drug: HGR4113

  • Placebo comparator
    Placebo 1200 mg Single Dose

    Single oral dosing of placebo 1200 mg

    Drug: Placebo

  • Experimental
    HGR4113 200 mg Multiple Dose

    Multiple oral dosing of HGR4113 200 mg, twice daily

    Drug: HGR4113

  • Placebo comparator
    Placebo 200 mg Multiple Dose

    Multiple oral dosing of placebo 200 mg, twice daily

    Drug: Placebo

  • Experimental
    HGR4113 400 mg Multiple Dose

    Multiple oral dosing of HGR4113 400 mg, twice daily

    Drug: HGR4113

  • Placebo comparator
    Placebo 400 mg Multiple Dose

    Multiple oral dosing of placebo 400 mg, twice daily

    Drug: Placebo

Interventions

  • DrugHGR4113

    Once-daily oral administration

  • DrugPlacebo

    Once-daily oral administration

  • DrugHGR4113

    Twice-daily oral administration

  • DrugPlacebo

    Twice-daily oral administration

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Assessment by Adverse Event Monitoring

    Number of participants with observed adverse events

    Time frame: Day 1 to 7 days after day of last administration

  2. Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination

    Number of participants with clinically significant change in physical examination

    Time frame: Day 1 to 7 days after day of last administration

  3. Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs

    Number of participants with clinically significant change in vital signs including blood pressure, heart rate, and body temperature

    Time frame: Day 1 to 7 days after day of last administration

  4. Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test

    Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, blood coagulation, and hormone tests

    Time frame: Day 1 to 7 days after day of last administration

  5. Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram

    Number of participants with clinically significant change in 12-lead electrocardiogram

    Time frame: Day 1 to 7 days after day of last administration

  6. Safety and Tolerability Assessment by Number of Participants with Change in Semen Parameters

    Number of participants with clinically significant change in semen assessed through semen volume, semen pH, sperm count, sperm concentration, sperm motility, and sperm morphology

    Time frame: From Screening to 12 weeks after day of last administration

  7. Pharmacokinetic Assessment by Maximum Plasma Concentration of HGR4113

    Maximum Plasma Concentration of HGR4113 (Cmax)

    Time frame: Hour 0 to 96

  8. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HGR4113 Over Dosing Interval

    Area Under the Plasma Concentration-Time Curve of HGR4113 Over Dosing Interval (AUCtau)

    Time frame: Hour 0 to 24

  9. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HGR4113 from Time Zero to the Last Measurable Point

    Area Under the Plasma Concentration-Time Curve of HGR4113 from Time Zero to the Last Measurable Point (AUClast)

    Time frame: Hour 0 to 96

  10. Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HGR4113 from Time Zero to Infinity

    Area Under the Plasma Concentration-Time Curve of HGR4113 from Time Zero to Infinity (AUCinf)

    Time frame: Hour 0 to 96

  11. Pharmacokinetic Assessment by Half-Life of HGR4113

    Half-life of HGR4113 (T1/2)

    Time frame: Hour 0 to 96

  12. Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HGR4113

    Time to Maximum Observed Plasma of HGR4113 (Tmax)

    Time frame: Hour 0 to 96

  13. Pharmacokinetic Assessment by Oral Clearance of HGR4113

    Oral Clearance of HGR4113 (CL/F)

    Time frame: Hour 0 to 96

  14. Pharmacokinetic Assessment by Apparent Volume of Distribution of HGR4113

    Volume of Distribution of HGR4113 (Vz/F)

    Time frame: Hour 0 to 96

Secondary outcomes

  1. Pharmacodynamic Assessment by Change in Paraoxonase 1 Activity

    Change in paraoxonase 1 activity

    Time frame: Day -1 to 17

  2. Pharmacodynamic Assessment by Change in Plasma Glucose

    Change in plasma glucose level

    Time frame: Day -1 to 17

  3. Pharmacodynamic Assessment by Change in Plasma HbA1c

    Change in plasma HbA1c level

    Time frame: Day -1 to 17

  4. Pharmacodynamic Assessment by Change in Plasma Insulin

    Change in plasma insulin level

    Time frame: Day -1 to 17

  5. Pharmacodynamic Assessment by Change in Plasma C-peptide

    Change in plasma c-peptide level

    Time frame: Day -1 to 17

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Kyung Sang Yu, MD, PhD · Contact
    • Kyung Sang Yu, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2024, 20 months after the start.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 20 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartActual
Nov 22, 2022
Primary completionEst.
Jul 31, 2024
CompletionEst.
Jan 31, 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642377
Lead sponsor
Glaceum
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Nov 22, 2022
Primary completion
Jul 31, 2024 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Youngah Kim
Contact
yakim116@glaceum.com
82-31-8002-2558
Kyung Sang Yu, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion